Mycophenolate Tablets to Prevent Immune Rejection of Transplants

Immunosuppressive therapy aims to prevent acute rejection and optimise the function of the transplanted organ. Mycophenolate sodium is a secondary metabolite produced by Penicillium brevicompactum, which has antibiotic and immunosuppressive properties used to prevent rejection of kidney transplants. It Inhibits inosine monophosphate dehydrogenase (IMPDH) and blocks the generation of guanosine nucleotides in the de novo pathway of DNA synthesis in the T cell. It is administered orally, at a recommended dose of 1.44 g per day. Mycophenolate sodium is available in 180-mg and 360-mg tablets. An enteric-coated formulation of Mycophenolate sodium is being developed and is currently in Phase IV clinical trial. This book provides insights on formulation development and in vitro evaluation aspects of Mycophenolate sodium enteric tablets which include HPLC analytical method development, compatibility studies, formulation development, evaluation of dosage forms, drug release and stability studies.